**Grand Pharmaceutical Group Limited**
**遠大醫藥集團有限公司***
*(Incorporated in Bermuda with limited liability)*
**(Stock Code: 00512)**

**VOLUNTARY ANNOUNCEMENT**

**CARGLUMIC ACID DISPERSIBLE TABLETS WAS GRANTED A DRUG REGISTRATION CERTIFICATE**

This announcement is made by the board of directors (the "**Board**") of Grand Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The Board is pleased to announce that Carglumic Acid Dispersible Tablets which is independently developed by the Group for the treatment of hyperammonemia in adults or children caused by N-acetylglutamate synthetase ("**NAGS**") deficiency, Isovaleric acidemia (IVA), methylmalonic acidemia ("**MMA**"), or propionic acidemia ("**PA**"), has been granted a drug registration certificate by the National Medical Products Administration of the People's Republic of China recently. The product is the first generic drug commercialized in China. It is a significant R&D progress of the Group in the direction of rare diseases in the field of cerebro-cardiovascular emergency.

Congenital hereditary hyperammonemia is a metabolic disorder syndrome characterized by abnormally elevated blood ammonia levels and central nervous system dysfunction caused by metabolic pathway-specific enzyme deficiency in the urea cycle or other than the urea cycle. Hyperammonemia is a clinical critical disease. Excessive blood ammonia concentration has strong toxicity to the nervous system, which can affect the energy metabolism of the nervous system, inhibit nerve conduction and cause neurological dysfunction. At the same time, it can also lead to cerebral edema or even brain herniation, causing irreversible damage to the brain. In severe cases, coma, breathing difficulties and even death may occur. There are two main causes of congenital hereditary hyperammonemia, one is the urea cycle disorder caused by the lack of key enzymes in the urea cycle system, such as NAGS deficiency; the other one is the urea cycle disorder caused by the organic acidemia that inhibits the activity of key enzymes in the urea cycle such as NAGS deficiency, caused by the lack of key enzymes in other metabolic pathways. At present, drugs are mainly used to reduce blood ammonia concentration to relieve the condition, and most patients need long-term medication. There are few targeted treatment drugs since this type of disease is a rare disease, and the average daily treatment cost reaches

thousands of RMB, indicating a heavy medical burden on patients.

Carboglutamic acid is a structural analogue of N-acetylglutamic acid ("**NAG**") and an allosteric activator of carbamyl phosphate synthase 1 (CPS1). It can combine with unsynthesized ammonium bicarbonate to generate NAG, thereby stimulating the urea cycle, helping ammonia to convert into urea, reducing blood ammonia concentration, and improving or preventing brain damage caused by hyperammonemia. Clinical trials have shown that Carglumic Acid Dispersible Tablets have significant curative effect and favorable safety on patients with hyperammonemia due to NAGS deficiency. It can quickly reduce the blood ammonia level, reduce the blood ammonia level to the normal range within 24 hours, and maintain the stability of the blood ammonia level for a long time. At present, Carglumic Acid Dispersible Tablets have been commercialized in many countries and regions such as Europe and the United States, and have been included in the Orphan Drug List of the US Food and Drug Administration ("**FDA**"). It is the first and only drug approved by the FDA for the treatment of hyperammonemia caused by PA and MMA. The Group's Carglumic Acid Dispersible Tablets is the first generic drug commercialized in China. It not only provides a new safe and effective treatment for the clinic, but is also expected to reduce the medical burden of patients with congenital hereditary hyperammonemia.

Cerebro-cardiovascular emergency is one of the key strategic planning directions in the field of pharmaceutical technology of the Group. Listed as "national essential drug production base", "emergency medicines manufacturer for national ready reserve" and "national centralized production base and construction unit for minority-variety medicines (drugs in short supply)", the Group have nearly 30 varieties in the field of cerebro-cardiovascular emergency, 14 of which are included in the national emergency drugs catalogue, and 16 of which are included in the shortage drugs catalogue, ranking the top in the industry in terms of product pipeline. Currently, there are more than 20 products under research in the field of cerebro-cardiovascular emergency. Among which, in the direction of rare diseases, apart from Carglumic Acid Dispersible Tablets that been approved for commercialization this time, the commercialization application of vigabatrin oral solution powder for the treatment of West's syndrome has been submitted, and the R&D of other drugs for rare diseases are also progressing smoothly. As one of the greatest medical challenges facing humanity, the clinical diagnosis and treatment of patients with rare diseases is more complex and difficult than other diseases. At present, only 5% of rare diseases in the world have effective treatments while the treatment costs are expensive. Most patients with rare diseases still face the dilemma of "no medicine available" or "exorbitant drug costs". In order to meet the clinical needs in the field of rare diseases, respond to the call of the government and society, and undertake the social responsibility of pharmaceutical companies, the Group will continue to increase the development of rare disease drugs, bring more safe and effective treatments to patients with rare diseases, and continue to contribute to reducing the burden on patients.

The Group always puts focus on the R&D of innovative products and advanced technologies. Adhering to a patient-centered and innovation-driven approach, the Group will continue to increase its investment in world-class innovative products and advanced technologies to meet unmet clinical needs and enrich its product pipeline and improve supply chain. The Group adopts the strategy of "global expansion and dual-cycle operation", forming a new pattern of domestic and international cycles that synergize with each other. In this way, the Group can make full use of its industrial advantages and R&D capabilities, to accelerate the commercialization process for innovative products and provide patients with more advanced and diverse treatment options globally.

**Warning:**

**The production, sales and corresponding profit of aforementioned product is subject to various factors such as market changes with uncertainty. Shareholders and prospective investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

*Note: The English transliteration of the Chinese name(s) in this announcement is included for information purpose only, and should not be regarded as the official English name(s) of such Chinese name(s).*

By order of the Board
**Grand Pharmaceutical Group Limited**
*Chairman*
**Dr. Tang Weikun**

Hong Kong, 12 September 2023

*As at the date of this announcement, the Board comprises four executive directors, namely, Dr. Tang Weikun, Mr. Zhou Chao, Dr. Shi Lin and Mr. Yang Guang, and three independent nonexecutive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Pei Geng and Mr. Hu Yebi.*

** For identification purpose only*